Ongoing Clinical News Today

The US accounts for the highest number of tissue engineered skin substitutes pipeline products...

/PRNewswire/ -- The "eClinical Solutions Market Size, Share & Trends Analysis Report by Product (eCOA, CTMS, EDC & CDMS), by Delivery Mode (Web-hosted,...

/PRNewswire/ -- The "eClinical Solutions Market Size, Share & Trends Analysis Report by Product (eCOA, CTMS, EDC & CDMS), by Delivery Mode (Web-hosted,...

/PRNewswire/ -- The "Lumakras Drug Clinical Insight & Sales Forecast 2026" report has been added to ResearchAndMarkets.coms offering. The report global...

/PRNewswire/ -- The "Lumakras Drug Clinical Insight & Sales Forecast 2026" report has been added to ResearchAndMarkets.coms offering. The report global...

Dublin, Nov. 24, 2021 (GLOBE NEWSWIRE) -- The "Lumakras Drug Clinical Insight & Sales Forecast 2026" report has been added to...

Hoolimata tõsiasjast, et erinevate respiratoorsete haiguste vastaste vaktsiinide katsetused on kestnud pikki aastakümneid, on paljud neist lõppenud suurema või väiksema fiaskoga. Muu hulgas on vaktsiinikandidaatide põrumist põhjustanud ka ohtlik fenomen nimega ADE – antikeha-sõltuv immuunpatoloogia ehk antikehade kaasabil tekkiv haiguse võimendumine (ingl antibody dependent enhancement), kirjutab Liis Orav.   Teadlased puutusid selle nähtusega kokku juba […]

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Gilead  and  Galapagos  announce  New  Commercialization  and  Development  Agreement  for  ... Galapagos NVDecember 15, 2020 GMT -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Re...

Share: -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing Clinical Trials -- -- Gilead will Pay Galapagos €160 million to Support Ongoing Development and Accelerated Co...

Galapagos NV: Gilead and Galapagos announce New Commercialization and Development Agreement for Jyseleca (filgotinib) -- Gilead will Not Advance Jyseleca for the Treatment of Rheumatoid Arthritis (RA) in the U.S. Following FDA Type A Meeting -- -- Galapagos to Assume Sole Responsibility in Europe for Jyseleca in RA and Ulcerative Colitis (UC) Plus Future Indications; Gilead to Receive Royalties on European Sales Starting in 2024 -- -- Galapagos to Assume Responsibility for Majority of Ongoing C...